These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 17620054)

  • 41. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osteoporosis prevention clinical study program.
    Delmas P; Gimona A
    Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sex steroids and bone turnover markers in men with symptomatic vertebral fractures.
    Tuck SP; Scane AC; Fraser WD; Diver MJ; Eastell R; Francis RM
    Bone; 2008 Dec; 43(6):999-1005. PubMed ID: 18817902
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
    Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
    Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
    Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
    Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
    Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM;
    J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women.
    Delmas PD; Confavreux E; Garnero P; Fardellone P; de Vernejoul MC; Cormier C; Arce JC
    Osteoporos Int; 2000; 11(2):177-87. PubMed ID: 10793878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN.
    Sowers MR; Finkelstein JS; Ettinger B; Bondarenko I; Neer RM; Cauley JA; Sherman S; Greendale GA;
    Osteoporos Int; 2003 Jan; 14(1):44-52. PubMed ID: 12577184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.